The latest edition of the PD(L)anner looks at clinical, regulatory, and commercial milestones in the field of PD-(L)1 inhibitors since we released our last report in September 2022. A major focus of this issue is combinations of inhibitors of PD-(L)1 and novel immuno-oncology mechanisms.
The latest edition of the PD(L)anner looks at clinical, regulatory, and commercial milestones in the field of PD-(L)1 inhibitors since we released our last report in September 2022. A major focus of this issue is combinations of inhibitors of PD-(L)1 and novel immuno-oncology mechanisms.
To even the most optimistic soul, 2022 was not a vintage year for the world of biopharma and medtech. Public markets continued their downward trajectory and many…
To even the most optimistic soul, 2022 was not a vintage year for the world of biopharma and medtech. Public markets continued their downward trajectory and many…
The JP Morgan Healthcare Conference 2023 was the first in-person iteration of the event since 2020. After a rather lacklustre 2022 conference, this year’s event started…
The JP Morgan Healthcare Conference 2023 was the first in-person iteration of the event since 2020. After a rather lacklustre 2022 conference, this year’s event started…
The new year is upon us! What should biopharma companies and investors expect from 2023? Can they hope for better than 2022 or will it be more of the same? We already…
The new year is upon us! What should biopharma companies and investors expect from 2023? Can they hope for better than 2022 or will it be more of the same? We already…
As the final big conference of the year, ASH is always something a harbinger of things to come. This year was no exception with plenty to keep pharma-watchers pondering…
As the final big conference of the year, ASH is always something a harbinger of things to come. This year was no exception with plenty to keep pharma-watchers pondering…
There are some things in life you want to be consistent and predictable. Interest rates. Train timetables. The weather. And if you work in the pharma industry, the…
